Parathyroid Hormone
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Parathyroid Hormone |
| DrugBank ID | DB05829 |
| Brand Names (EU) | Natpar |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.98% |
Approved Indication (EMA)
Natpar is indicated as adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | migraine disorder | 99.98% | DL |
| 2 | migraine with brainstem aura | 99.97% | DL |
| 3 | amenorrhea (disease) | 99.97% | DL |
| 4 | Raynaud disease | 99.84% | DL |
| 5 | non-syndromic esophageal malformation | 99.80% | DL |
| 6 | migraine with or without aura, susceptibility to | 99.75% | DL |
| 7 | esophageal disease | 99.74% | DL |
| 8 | atrophoderma vermiculata | 99.68% | DL |
| 9 | ulerythema ophryogenesis | 99.59% | DL |
| 10 | erectile dysfunction (disease) | 99.07% | DL |
| 11 | esophageal ulcer | 99.01% | DL |
| 12 | sciatic neuropathy | 98.95% | DL |
| 13 | open-angle glaucoma | 98.77% | DL |
| 14 | primary hereditary glaucoma | 98.68% | DL |
| 15 | homozygous familial hypercholesterolemia | 98.67% | DL |
| 16 | postural orthostatic tachycardia syndrome | 98.66% | DL |
| 17 | lesion of sciatic nerve | 98.64% | DL |
| 18 | infectious bovine rhinotracheitis | 98.64% | DL |
| 19 | malignant catarrh | 98.64% | DL |
| 20 | antithrombin deficiency type 2 | 98.53% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.